Table 2.
Summary of published survival results using CuATSM therapeutically in SOD1 mouse models of ALS.
| Mouse Model | CuATSM Dosing Regimen | Median Age at Death |
||||
|---|---|---|---|---|---|---|
| Vehicle Control | Treatment | % Life Extension | p value | Reference | ||
| Published Results | ||||||
| B6SJLTg(SOD1*G93A)dl1Gur x B6SJL-Tg(Prnp-CCS)17Jlel/J | 30 mg/kg 2x daily prenatally to mothers, then starting at p5 | 14 days | 660 days | >4000% | <0.0001 | Williams et al., 2016 |
| B6SJL-Tg(SOD1*G93A)1Gur | 100 mg/kg 2x daily starting at p50 | 133 days | 155 days | 16.5% | <0.0001 | Williams et al., 2016 |
| B6.Cg-Tg(SOD1*G37R)29Dpr/J | 30 mg/kg/day starting at p40 | ≈180 days based on publication figure | ≈210 days based on publication figure | ≈17%, though reports 12% | 0.006 | Roberts et al., 2014 |
| B6SJLTg(SOD1*G93A)dl1Gur | 30 mg/kg/day starting at p140 | 263 days | 300 days | 14% | 0.001 | Soon et al., 2011 |
| B6SJL-Tg(SOD1*G93A)1Gur | 100 mg/kg/day starting at p50 | 130 days | 141 days | 8% | <0.0001 | Hilton et al., 2017 |
| Current Report | ||||||
| B6SJL-Tg(SOD1*G93A)1Gur | 30 mg/kg/day starting at p50 | 125 | 132 | 5% | 0.15 | Current report |
| B6SJL-Tg(SOD1*G93A)1Gur (male only) | 30 mg/kg/day starting at p50 | 117 | 127 | 9% | 0.07 | Current report |
| B6SJL-Tg(SOD1*G93A)1Gur (female only) | 30 mg/kg/day starting at p50 | 129 | 137 | 6% | 0.60 | Current report |